Impact of rare structural variant events in newly diagnosed multiple myeloma.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
08 Nov 2023
Historique:
accepted: 07 11 2023
received: 06 04 2023
revised: 19 07 2023
medline: 8 11 2023
pubmed: 8 11 2023
entrez: 8 11 2023
Statut: aheadofprint

Résumé

Whole genome sequencing (WGS) of newly diagnosed multiple myeloma patients (NDMM) has shown recurrent structural variant (SV) involvement in distinct regions of the genome (i.e. hotspots) and causing recurrent copy number alterations. Together with canonical immunoglobulin translocations, these SVs are recognized as "recurrent SVs". More than half SVs were not involved in recurrent events. The significance of these "rare SVs" has not been previously examined. In this study, we utilize 752 WGS and 591 RNA-seq data from NDMM patients to determine the role of rare SVs in myeloma pathogenesis. 94% of patients harbored at least one rare SV event. Rare SVs showed an SV-class specific enrichment within genes and superenhancers associated with outlier gene expression. Furthermore, known myeloma driver genes recurrently impacted by point mutations were dysregulated by rare SVs. Overall, we demonstrate the association of rare SVs with aberrant gene expression supporting a potential driver role in myeloma pathogenesis.

Identifiants

pubmed: 37939148
pii: 730046
doi: 10.1158/1078-0432.CCR-23-1045
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : UpdateOf

Auteurs

Monika Chojnacka (M)

Sylvester Comprehensive Cancer Center, Miami, FL, United States.

Benjamin Diamond (B)

Sylvester Comprehensive Cancer Center, Miami, FL, United States.

Bachisio Ziccheddu (B)

University of Miami Miller School of Medicine, Miami, FL, United States.

Even Rustad (E)

Oslo University Hospital, Oslo, Norway.

Kylee Maclachlan (K)

Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Marios Papadimitriou (M)

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

Eileen M Boyle (EM)

University of Arkansas for Medical Sciences, New-York, AR, United States.

Patrick Blaney (P)

NYU Perlmutter Cancer Center, New York, NY, United States.

Saad Usmani (S)

Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Gareth Morgan (G)

New York University Langone Medical Center, New York, NY, United States.

Ola Landgren (O)

Sylvester Comprehensive Cancer Center, Miami, FL, United States.

Francesco Maura (F)

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

Classifications MeSH